All-Patient General Drug Use Surveillance of Rozlytrek Capsule -ROS1 fusion gene-positive unresectable advanced or recurrent non-small cell lung cancer-
Latest Information Update: 03 Aug 2022
At a glance
- Drugs Entrectinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Chugai Pharmaceutical
- 01 Aug 2022 Status changed from not yet recruiting to recruiting.
- 19 Jan 2022 New trial record